DK0478363T3 - Hidtil ukendte sulfonamidfibrinogenreceptorantagonister - Google Patents

Hidtil ukendte sulfonamidfibrinogenreceptorantagonister

Info

Publication number
DK0478363T3
DK0478363T3 DK91308850.6T DK91308850T DK0478363T3 DK 0478363 T3 DK0478363 T3 DK 0478363T3 DK 91308850 T DK91308850 T DK 91308850T DK 0478363 T3 DK0478363 T3 DK 0478363T3
Authority
DK
Denmark
Prior art keywords
opt
substd
alkyl
aryl
het1
Prior art date
Application number
DK91308850.6T
Other languages
Danish (da)
English (en)
Inventor
George D Hartman
Wasyl Halczenko
Melissa S Egbertson
William L Laswell
Mark E Duggan
Original Assignee
Merck & Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck & Co Inc filed Critical Merck & Co Inc
Application granted granted Critical
Publication of DK0478363T3 publication Critical patent/DK0478363T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/01—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms
    • C07C311/02—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
    • C07C311/03—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton having the nitrogen atoms of the sulfonamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C311/06—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton having the nitrogen atoms of the sulfonamide groups bound to hydrogen atoms or to acyclic carbon atoms to acyclic carbon atoms of hydrocarbon radicals substituted by carboxyl groups
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/01—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms
    • C07C311/12—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an unsaturated carbon skeleton containing rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/01—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms
    • C07C311/12—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an unsaturated carbon skeleton containing rings
    • C07C311/13—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an unsaturated carbon skeleton containing rings the carbon skeleton containing six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/20—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms
    • C07D211/22—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pyrrole Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Pyridine Compounds (AREA)
  • Materials For Medical Uses (AREA)
  • External Artificial Organs (AREA)
DK91308850.6T 1990-09-27 1991-09-27 Hidtil ukendte sulfonamidfibrinogenreceptorantagonister DK0478363T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US58913090A 1990-09-27 1990-09-27
US75064791A 1991-08-30 1991-08-30

Publications (1)

Publication Number Publication Date
DK0478363T3 true DK0478363T3 (da) 1997-05-12

Family

ID=27080454

Family Applications (1)

Application Number Title Priority Date Filing Date
DK91308850.6T DK0478363T3 (da) 1990-09-27 1991-09-27 Hidtil ukendte sulfonamidfibrinogenreceptorantagonister

Country Status (32)

Country Link
US (5) US5292756A (fr)
EP (2) EP0743302B1 (fr)
JP (2) JPH0794425B2 (fr)
KR (1) KR100216939B1 (fr)
CN (1) CN1038748C (fr)
AT (1) ATE150454T1 (fr)
AU (1) AU655436B2 (fr)
BG (1) BG61810B1 (fr)
CA (1) CA2052073C (fr)
CY (1) CY2048B1 (fr)
DE (2) DE69125235T2 (fr)
DK (1) DK0478363T3 (fr)
ES (2) ES2133892T3 (fr)
FI (2) FI108295B (fr)
GR (2) GR3023226T3 (fr)
HR (1) HRP930779B1 (fr)
IE (1) IE913383A1 (fr)
IL (1) IL99540A (fr)
LU (1) LU90505I2 (fr)
LV (1) LV12089B (fr)
NL (1) NL990040I2 (fr)
NO (2) NO177702C (fr)
NZ (1) NZ239846A (fr)
PL (1) PL172687B1 (fr)
PT (1) PT99098B (fr)
RO (1) RO116621B1 (fr)
RU (1) RU2116296C1 (fr)
SI (1) SI9210306B (fr)
SK (1) SK281233B6 (fr)
UA (1) UA44222C2 (fr)
WO (1) WO1993019046A1 (fr)
YU (1) YU48912B (fr)

Families Citing this family (140)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ239846A (en) * 1990-09-27 1994-11-25 Merck & Co Inc Sulphonamide derivatives and pharmaceutical compositions thereof
US5645815A (en) * 1991-02-08 1997-07-08 Diatide, Inc. Radiolabled compounds for thrombus imaging
US5321034A (en) * 1991-05-07 1994-06-14 Merck & Co., Inc. Fibrinogen receptor antagonists
AU666318B2 (en) * 1991-06-28 1996-02-08 Smithkline Beecham Corporation Bicyclic fibrinogen antagonists
US5939412A (en) * 1992-06-26 1999-08-17 Smithkline Beecham Corporation Bicyclic fibrinogen antagonists
EP0605499B1 (fr) * 1991-09-24 1997-11-12 Janssen Pharmaceutica N.V. PROCEDE DE PREPARATION D'IMIDAZO 4,5,1-jk] 1,4]-BENZODIAZEPIN-2(1H -)-THIONES A PURETE ENANTIOMERE
US5264457A (en) * 1992-02-14 1993-11-23 G. D. Searle & Co. Phenyl amidines sulfonamides useful as platelet aggregation inhibitors
TW224462B (fr) * 1992-02-24 1994-06-01 Squibb & Sons Inc
US5206373A (en) * 1992-02-28 1993-04-27 Merck & Co., Inc. Process for preparing fibrinogen receptor antagonists
US5312923A (en) * 1992-02-28 1994-05-17 Merck & Co., Inc. Process for preparing fibrinogen receptor antagonists
US5504106A (en) * 1992-06-25 1996-04-02 G. D. Searle & Co. Phenyl amidine alkanoic acids and lactones useful as platelet aggregation inhibitors
WO1994008962A1 (fr) * 1992-10-14 1994-04-28 Merck & Co., Inc. Antagonistes des recepteurs du fibrinogene
JP3322878B2 (ja) * 1992-10-14 2002-09-09 メルク エンド カンパニー インコーポレーテッド フィブリノーゲンレセプターアンタゴニスト
US5358956A (en) * 1992-10-14 1994-10-25 Merck & Co., Inc. Fibrinogen receptor antagonists
US5340798A (en) * 1992-10-14 1994-08-23 Merck & Co., Inc. Fibrinogen receptor antagonists
WO1994012181A1 (fr) * 1992-12-01 1994-06-09 Merck & Co., Inc. Antagonistes des recepteurs du fibrinogene
US5652242A (en) * 1993-03-29 1997-07-29 Zeneca Limited Heterocyclic derivatives
US5750754A (en) * 1993-03-29 1998-05-12 Zeneca Limited Heterocyclic compounds
US5753659A (en) * 1993-03-29 1998-05-19 Zeneca Limited Heterocyclic compouds
WO1994022834A1 (fr) * 1993-03-29 1994-10-13 Zeneca Limited Derives heterocycliques utilises comme inhibiteurs d'agregation plaquettaire
GB9406144D0 (en) * 1993-03-29 1994-05-18 Zeneca Ltd Heterocyclic compounds
US5441952A (en) * 1993-04-05 1995-08-15 Merck & Co., Inc. Fibrinogen receptor antagonists
US5334596A (en) * 1993-05-11 1994-08-02 Merck & Co., Inc. Fibrinogen receptor antagonists
SE9301916D0 (sv) * 1993-06-03 1993-06-03 Ab Astra New peptides derivatives
US6984627B1 (en) * 1993-06-03 2006-01-10 Astrazeneca Ab Peptide derivatives
US5612355A (en) * 1993-06-23 1997-03-18 G. D. Searle & Co. Phenyl amidine lactones useful as platelet aggregation inhibitors
GB9313285D0 (en) * 1993-06-28 1993-08-11 Zeneca Ltd Acid derivatives
US5463011A (en) * 1993-06-28 1995-10-31 Zeneca Limited Acid derivatives
GB9313268D0 (en) * 1993-06-28 1993-08-11 Zeneca Ltd Chemical compounds
EP0706999A1 (fr) * 1993-06-30 1996-04-17 Sumitomo Pharmaceuticals Company, Limited Nouveau derive de piperidine
US5397791A (en) * 1993-08-09 1995-03-14 Merck & Co., Inc. Fibrinogen receptor antagonists
AU7862794A (en) * 1993-10-19 1995-05-08 Sumitomo Pharmaceuticals Company, Limited 2,3-diaminopropionic acid derivative
US5523302A (en) * 1993-11-24 1996-06-04 The Du Pont Merck Pharmaceutical Company Aromatic compounds containing basic and acidic termini useful as fibrinogen receptor antagonists
US5849736A (en) * 1993-11-24 1998-12-15 The Dupont Merck Pharmaceutical Company Isoxazoline and isoxazole fibrinogen receptor antagonists
US5446056A (en) * 1993-11-24 1995-08-29 The Du Pont Merck Pharmaceutical Company Isoxazoline compounds useful as fibrinogen receptor antagonists
US5563158A (en) * 1993-12-28 1996-10-08 The Dupont Merck Pharmaceutical Company Aromatic compounds containing basic and acidic termini useful as fibrinogen receptor antagonists
MA23420A1 (fr) * 1994-01-07 1995-10-01 Smithkline Beecham Corp Antagonistes bicycliques de fibrinogene.
US5821241A (en) * 1994-02-22 1998-10-13 Merck & Co., Inc. Fibrinogen receptor antagonists
CA2190870A1 (fr) * 1994-05-27 1995-12-07 George D. Hartman Composes inhibiteurs de la resorption osseuse induite par osteoclaste
US6458784B1 (en) 1994-06-29 2002-10-01 Smithkline Beecham Corporation Vitronectin receptor antagonists
US5451578A (en) * 1994-08-12 1995-09-19 Merck & Co., Inc. Fibrinogen receptor antagonists
US5525617A (en) * 1994-08-24 1996-06-11 Merck & Co., Inc. Fibrinogen receptor antagonists
US5494921A (en) * 1994-09-16 1996-02-27 Merck & Co., Inc. Fibrinogen receptor antagonists
WO1996018602A1 (fr) * 1994-12-13 1996-06-20 Smithkline Beecham Corporation Antagonistes bicycliques du fibrinogene
WO1996019223A1 (fr) * 1994-12-22 1996-06-27 Smithkline Beecham Corporation Antagonistes des recepteurs du fibrinogene
US5719144A (en) * 1995-02-22 1998-02-17 Merck & Co., Inc. Fibrinogen receptor antagonists
ZA963391B (en) * 1995-05-24 1997-10-29 Du Pont Merck Pharma Isoxazoline fibrinogen receptor antagonists.
IL118007A0 (en) * 1995-05-24 1996-08-04 Du Pont Merck Pharma Isoxazoline compounds pharmaceutical compositions containing them and their use
US5977101A (en) * 1995-06-29 1999-11-02 Smithkline Beecham Corporation Benzimidazoles/Imidazoles Linked to a Fibrinogen Receptor Antagonist Template Having Vitronectin Receptor Antagonist Activity
CZ293323B6 (cs) * 1995-08-30 2004-04-14 G. D. Searle & Co. Meta-guanidinové, močovinové, thiomočovinové nebo azacyklické deriváty aminobenzoové kyseliny jako antagonisty integrinů
US6100423A (en) * 1995-08-30 2000-08-08 G. D. Searle & Co. Amino benzenepropanoic acid compounds and derivatives thereof
US5789421A (en) * 1995-10-26 1998-08-04 Merck & Co., Inc. Fibrinogen receptor antagonist
TW385248B (en) * 1995-10-27 2000-03-21 Merck & Co Inc Pharmaceutical compositions for intravenous administration for inhibiting platelet aggregation
US5733919A (en) * 1995-10-27 1998-03-31 Merck & Co., Inc. Compositions for inhibiting platelet aggregation
US5972967A (en) * 1996-10-23 1999-10-26 Merck & Co., Inc. Compositions for inhibiting platelet aggregation
DE19548709A1 (de) * 1995-12-23 1997-07-03 Merck Patent Gmbh Tyrosinderivate
US5952306A (en) * 1996-01-16 1999-09-14 Merck & Co., Inc. Integrin receptor antagonists
US5780480A (en) * 1996-02-28 1998-07-14 Merck & Co., Inc. Fibrinogen receptor antagonists
AU712082B2 (en) * 1996-02-28 1999-10-28 Merck & Co., Inc. Fibrinogen receptor antagonists
WO1997035579A1 (fr) * 1996-03-27 1997-10-02 Merck & Co., Inc. Procede d'inhibition de la formation de caillots
WO1997036862A1 (fr) * 1996-03-29 1997-10-09 G.D. Searle & Co. DERIVES DE PHENYLENE META-SUBSTITUES, UTILISES COMME ANTAGONISTES OU INHIBITEURS DE L'INTEGRINE ALPHAvBETA¿3?
DE69705829T2 (de) * 1996-03-29 2002-04-04 G.D. Searle & Co., Chicago Meta-substituierte phenylsulphonamidderivate
PT891325E (pt) * 1996-03-29 2002-07-31 Searle & Co Derivados do acido fenilpropanoico para-substituido como antagonistas de integrina
EP0889875B1 (fr) * 1996-03-29 2001-06-20 G.D. Searle & Co. Derives de l'acide alcanoique de cyclopropyle
DK0894084T3 (da) * 1996-03-29 2002-10-14 Searle & Co Kanelsyrederivater og deres anvendelse som integrinantagonister
IL121202A (en) 1996-07-01 2001-08-26 Lilly Co Eli Hypoglycemic and hypolipidemic compounds, process for their preparation, pharmaceutial compositions comprising same, and uses thereof
US6653331B2 (en) * 1996-07-03 2003-11-25 Pharmacia & Upjohn Company Targeted drug delivery using sulfonamide derivatives
US5977138A (en) * 1996-08-15 1999-11-02 Schering Corporation Ether muscarinic antagonists
US6004955A (en) * 1996-08-15 1999-12-21 Dupont Pharmaceuticals Company Cyclic carbamates and isoxazolidines as IIb/IIIa antagonists
WO1998006707A1 (fr) * 1996-08-15 1998-02-19 Dupont Pharmaceuticals Company Carbamates et isoxazolidines cycliques antagonistes de l'iib/iiia
US5900414A (en) * 1996-08-29 1999-05-04 Merck & Co., Inc. Methods for administering integrin receptor antagonists
US5978698A (en) * 1996-10-08 1999-11-02 Merck & Co., Inc. Angioplasty procedure using nonionic contrast media
AU754936B2 (en) * 1996-11-27 2002-11-28 Aventis Pharmaceuticals Inc. Pharmaceutical composition comprising a compound having anti-Xa activity and a platelet aggregation antagonist compound
US5981584A (en) * 1997-02-06 1999-11-09 Merck & Co., Inc. Fibrinogen receptor antagonist prodrugs
US6294549B1 (en) 1997-07-23 2001-09-25 Merck & Co., Inc. Method for eliciting an αvβ5 or dual αvβ3/αvβ5 antagonizing effect
JP2001524481A (ja) * 1997-11-26 2001-12-04 デュポン ファーマシューティカルズ カンパニー αＶβ３アンタゴニストとしての１，３，４−チアジアゾール類および１，３，４−オキサジアゾール類
US6623981B2 (en) * 1998-01-27 2003-09-23 Bristol-Myers Squibb Company Detection of patients at risk for developing integrin antagonist/agonist mediated disease states
US6583157B2 (en) 1998-01-29 2003-06-24 Tularik Inc. Quinolinyl and benzothiazolyl modulators
WO1999038845A1 (fr) 1998-01-29 1999-08-05 Tularik Inc. MODULATEURS DU RECEPTEUR ACTIVE DE LA PROLIFERATION DES PEROXYSOMES (PPARη)
JP2002501936A (ja) * 1998-02-02 2002-01-22 メルク エンド カムパニー インコーポレーテッド 低分子量ヘパリンをＧＰＩＩｂ／ＩＩＩａ拮抗物質と組合わせて使用する血小板凝集の抑制
US6136794A (en) * 1998-02-02 2000-10-24 Merck & Co., Inc. Platelet aggregation inhibition using low molecular weight heparin in combination with a GP IIb/IIIa antagonist
US6117842A (en) * 1998-03-09 2000-09-12 Merck & Co., Inc. Fibrinogen receptor antagonists
US6136804A (en) * 1998-03-13 2000-10-24 Merck & Co., Inc. Combination therapy for treating, preventing, or reducing the risks associated with acute coronary ischemic syndrome and related conditions
WO1999050249A2 (fr) * 1998-04-01 1999-10-07 Du Pont Pharmaceuticals Company Antagonistes de l'integrine
EP1091945A1 (fr) 1998-06-29 2001-04-18 Du Pont Pharmaceuticals Company Isoxazolidines et carbamates cycliques utilises comme antagonistes de iib/iiia
US6271419B1 (en) * 1998-11-04 2001-08-07 Rhodia Chimie Process and reagent useful for the synthesis of sulphanilide which is perhalogenated on the carbon borne by the sulphur atom of the sulphanilide function
IL143928A0 (en) * 1999-01-22 2002-04-21 Elan Pharm Inc Fused ring heteroaryl and heterocyclic compounds which inhibit leukocyte adhesion mediated by vla-4
CA2357781A1 (fr) 1999-01-22 2000-07-27 Elan Pharmaceuticals, Inc. Composes inhibant l'adhesion leucocytaire provoquee par vla-4
US6492372B1 (en) 1999-01-22 2002-12-10 Elan Pharmaceuticals, Inc. Heteroaryl, heterocyclic and aryl compounds which inhibit leukocyte adhesion mediated by VLA-4
US6436904B1 (en) 1999-01-25 2002-08-20 Elan Pharmaceuticals, Inc. Compounds which inhibit leukocyte adhesion mediated by VLA-4
KR100377557B1 (ko) * 1999-02-12 2003-03-26 주식회사 엘지생명과학 아실 구아니딘 작용기를 갖는 선택적 트롬빈 억제제
KR100377558B1 (ko) * 1999-02-12 2003-03-26 주식회사 엘지생명과학 피페리딘 작용기를 갖는 선택적 트롬빈 억제제
CA2361162A1 (fr) 1999-03-01 2000-09-08 Elan Pharmaceuticals, Inc. Derives de l'acide alpha-aminoacetique antagonistes du recepteur alpha 4 beta 7
US6348504B1 (en) 1999-03-30 2002-02-19 Richard E. Olson Oxime ethers as IIb/IIa antagonists
US7041691B1 (en) 1999-06-30 2006-05-09 Amgen Inc. Compounds for the modulation of PPARγ activity
EA006227B1 (ru) 1999-12-10 2005-10-27 Пфайзер Продактс Инк. СОЕДИНЕНИЯ ПИРРОЛО[2,3-d]ПИРИМИДИНА
WO2001047875A1 (fr) * 1999-12-27 2001-07-05 Ortho-Mcneil Pharmaceutical, Inc. Derives d'aminoalkylamide substitues utilises en tant qu'antagonistes de l'hormone folliculostimulante
RU2245876C2 (ru) * 2000-03-21 2005-02-10 Дзе Проктер Энд Гэмбл Компани Производные сульфонамидов и фармацевтическая композиция на их основе
WO2001082916A2 (fr) * 2000-05-03 2001-11-08 Tularik Inc. Compositions therapeutiques combinees et leurs methodes d'utilisation
US20030171399A1 (en) * 2000-06-28 2003-09-11 Tularik Inc. Quinolinyl and benzothiazolyl modulators
US7452870B2 (en) * 2000-08-21 2008-11-18 Inspire Pharmaceuticals, Inc. Drug-eluting stents coated with P2Y12 receptor antagonist compound
US7018985B1 (en) 2000-08-21 2006-03-28 Inspire Pharmaceuticals, Inc. Composition and method for inhibiting platelet aggregation
PL365729A1 (en) * 2000-08-30 2005-01-10 Pharmacia Corporation Gem-substituted alpha v beta 3 integrin antagonists
US6531494B1 (en) 2001-08-29 2003-03-11 Pharmacia Corporation Gem-substituted αvβ3 antagonists
US7067539B2 (en) 2001-02-08 2006-06-27 Schering Corporation Cannabinoid receptor ligands
US7507767B2 (en) 2001-02-08 2009-03-24 Schering Corporation Cannabinoid receptor ligands
CA2449054C (fr) * 2001-05-30 2011-01-04 The Scripps Research Institute Liposome de ciblage d'integrine pour liberation d'acide nucleique
CA2475434C (fr) * 2002-02-07 2011-04-05 Hitoshi Endou Derives d'amino-acides aromatiques et compositions medicamenteuses
US6770660B2 (en) * 2002-05-06 2004-08-03 Artery Llc Method for inhibiting platelet aggregation
TW200307671A (en) * 2002-05-24 2003-12-16 Elan Pharm Inc Heteroaryl compounds which inhibit leukocyte adhesion mediated by α 4 integrins
TWI281470B (en) * 2002-05-24 2007-05-21 Elan Pharm Inc Heterocyclic compounds which inhibit leukocyte adhesion mediated by alpha4 integrins
CN100422147C (zh) * 2002-11-01 2008-10-01 北京天衡药物研究院 一种制备0-取代磺酰酪氨酸类化合物的方法
EP1569916B1 (fr) * 2002-11-15 2009-01-07 Cadila Healthcare Ltd. Derives d'aralkyle substitues
CN101353321A (zh) * 2002-11-21 2009-01-28 辉瑞产品公司 3-氨基-哌啶衍生物及其制备方法
US7223761B2 (en) 2003-10-03 2007-05-29 Amgen Inc. Salts and polymorphs of a potent antidiabetic compound
US7335648B2 (en) * 2003-10-21 2008-02-26 Inspire Pharmaceuticals, Inc. Non-nucleotide composition and method for inhibiting platelet aggregation
US7749981B2 (en) * 2003-10-21 2010-07-06 Inspire Pharmaceuticals, Inc. Drug-eluting stents coated with non-nucleotide P2Y12 receptor antagonist compound
US7504497B2 (en) * 2003-10-21 2009-03-17 Inspire Pharmaceuticals, Inc. Orally bioavailable compounds and methods for inhibiting platelet aggregation
WO2005040174A1 (fr) * 2003-10-21 2005-05-06 Inspire Pharmaceuticals, Inc. Composes tetrahydro-furo[3,4d]dioxole, et compositions et procede pour inhiber une agregation plaquettaire
DE10356346A1 (de) * 2003-11-28 2005-06-23 TransMIT Gesellschaft für Technologietransfer mbH Erfindung betreffend Prophylaxe und Therapie von Erkrankungen, die durch Thrombusbildung verusacht oder mit versacht werden
US20050250820A1 (en) * 2004-03-08 2005-11-10 Amgen Inc. Therapeutic modulation of PPARgamma activity
US7932376B2 (en) 2005-05-05 2011-04-26 Inspire Pharmaceuticals, Inc. Pyrimidine-based non-nucleotide composition and method for inhibiting platelet aggregation
CN1330636C (zh) * 2005-09-26 2007-08-08 鲁南制药集团股份有限公司 盐酸替罗非班中间体的合成方法
BRPI0616643A2 (pt) * 2005-09-29 2011-06-28 Elan Pharm Inc compostos de carbamato que inibem a adesão leucocitária mediada por vla-4
NZ567270A (en) * 2005-09-29 2011-06-30 Elan Pharm Inc Pyrimidinyl amide compounds which inhibit leukocyte adhesion mediated by VLA-4
KR20080100271A (ko) * 2006-02-27 2008-11-14 엘란 파마슈티칼스, 인크. Ｖｌａ-4에 의해 매개되는 백혈구 부착을 억제하는 피리미디닐 술폰아미드 화합물
CA2673683C (fr) 2007-01-11 2014-07-29 Critical Outcome Technologies, Inc. Composes et methode de traitement un cancer
US20100297621A1 (en) * 2007-06-20 2010-11-25 University Of Utah Research Foundation Use of pre-mrna splicing in platelet cells for the diagnosis of disease
CA2710039C (fr) 2007-12-26 2018-07-03 Critical Outcome Technologies, Inc. Semicarbazones, thiosemicarnazones et composes associes, et methodes de traitement du cancer
CA2730890C (fr) 2008-07-17 2018-05-15 Critical Outcome Technologies Inc. Composes inhibiteurs et procedes de traitement du cancer
WO2010059244A2 (fr) 2008-11-21 2010-05-27 Iroko Pharmaceuticals, Llc Procédé pour réduire la thrombocytopénie et la mortalité associée à la thrombocytopénie
CA2755569A1 (fr) * 2009-03-18 2010-09-23 Medicure International Inc. Preparation pharmaceutique transdermique et administration de tirofiban
EP2424841A1 (fr) * 2009-04-27 2012-03-07 Elan Pharmaceuticals Inc. Antagonistes à base de pyridinone d'intégrines alpha-4
CA2794952C (fr) 2010-04-01 2018-05-15 Critical Outcome Technologies Inc. Composes et methodes pour le traitement du vih
US9345793B2 (en) 2011-08-17 2016-05-24 Piramal Imaging Sa Compounds for binding to the platelet specific glycoprotein IIB/IIIA and their use for imaging of thrombi
CN103848775A (zh) * 2012-11-29 2014-06-11 上海信谊药厂有限公司 制备盐酸替罗非班的方法
CA2900595A1 (fr) 2013-02-12 2014-08-21 Bayer Pharma Aktiengesellschaft Chelates metalliques pour la liaison a la glycoproteine iib/iiia specifique des plaquettes
DE102014108210A1 (de) 2014-06-11 2015-12-17 Dietrich Gulba Rodentizid
CN115181058B (zh) * 2021-04-01 2024-06-11 武汉武药科技有限公司 组合物及其质量控制方法
EP4070658A1 (fr) 2021-04-06 2022-10-12 BIORoxx GmbH Utilisation de composés anticoagulants comme rodenticides

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1062206B (it) * 1974-02-01 1983-09-20 Rotta Research Lab S P A A S Derivati della tirosina attivi sulla muscolatura liscia
DE2549999A1 (de) * 1975-11-07 1977-05-12 Boehringer Mannheim Gmbh Piperidin-derivate und verfahren zu ihrer herstellung
US4064125A (en) * 1976-10-29 1977-12-20 E. R. Squibb And Sons, Inc. Substituted amides having antiinflammatory activity
US4098889A (en) * 1977-09-01 1978-07-04 The Dow Chemical Company Antithrombotic 2-(aminoalkylthio)-N,N'-p-phenylenebissulfonamides
DE2809377A1 (de) * 1978-03-04 1979-09-13 Boehringer Mannheim Gmbh Phenoxyalkylcarbonsaeure-derivate, verfahren zu deren herstellung sowie diese verbindungen enthaltende arzneimittel
IL60129A0 (en) * 1979-05-23 1980-07-31 Wuelfing J Kg Phenylsulphonamide derivatives,their preparation and pharmaceutical compositions containing them
FR2482528A1 (fr) * 1980-05-14 1981-11-20 Heuliez Henri Holding Vehicule automobile a deux modes de traction, notamment autobus
US5174994A (en) * 1985-11-11 1992-12-29 Leuven Research & Development Vzw Pharmaceutical composition having thrombolytic activity
KR880007441A (ko) * 1986-12-11 1988-08-27 알렌 제이.스피겔 스피로-치환된 글루타르아미드 이뇨제
PH25458A (en) * 1987-08-24 1991-07-01 Eisai Co Ltd Piperidine derivatives, therapeutic, preventive agents
JP2764264B2 (ja) * 1987-10-01 1998-06-11 株式会社ミドリ十字 線溶活性増強剤
US5053393A (en) * 1988-07-20 1991-10-01 Monsanto Company Novel platelet-aggregation inhibitor
US4992463A (en) * 1988-07-20 1991-02-12 Monsanto Company Thienyl peptide mimetic compounds which are useful in inhibiting platelet aggregation
US5084466A (en) * 1989-01-31 1992-01-28 Hoffmann-La Roche Inc. Novel carboxamide pyridine compounds which have useful pharmaceutical utility
CA2008116C (fr) * 1989-02-23 2001-11-20 Thomas Weller Derives de glycine
CA1335361C (fr) * 1989-05-24 1995-04-25 Andrei Z. Budzynski Complexes diriges contre les thrombus et formes d'activateurs du plasminogene et de fragments de fibrine
US5061693A (en) * 1989-07-28 1991-10-29 Merck & Co., Inc. Fibrinogen receptor antagonists
US5023233A (en) * 1989-07-28 1991-06-11 Merck & Co., Inc. Fibrinogen receptor antagonists
DE4009506A1 (de) * 1990-03-24 1991-09-26 Hoechst Ag Hydantoinderivate
US5064814A (en) * 1990-04-05 1991-11-12 Rhone-Poulenc Rorer Pharmaceuticals Inc. Anti-thrombotic peptide and pseudopeptide derivatives
NZ239846A (en) * 1990-09-27 1994-11-25 Merck & Co Inc Sulphonamide derivatives and pharmaceutical compositions thereof

Also Published As

Publication number Publication date
US5880136A (en) 1999-03-09
EP0743302A2 (fr) 1996-11-20
LV12089A (lv) 1998-07-20
LU90505I2 (fr) 2000-03-20
WO1993019046A1 (fr) 1993-09-30
FI20011201A7 (fi) 2001-06-06
US5658929A (en) 1997-08-19
HK1000509A1 (en) 1998-04-03
LV12089B (en) 1998-11-20
ATE150454T1 (de) 1997-04-15
NL990040I1 (nl) 2000-02-01
NO913784D0 (no) 1991-09-26
SK281233B6 (sk) 2001-01-18
JP2812431B2 (ja) 1998-10-22
ES2133892T3 (es) 1999-09-16
EP0478363B1 (fr) 1997-03-19
KR100216939B1 (ko) 1999-09-01
HRP930779A2 (en) 1997-02-28
YU30692A (sh) 1995-10-24
CY2048B1 (en) 1998-04-30
CN1069971A (zh) 1993-03-17
YU48912B (sh) 2002-11-15
BG99020A (bg) 1995-07-28
SK102394A3 (en) 1995-04-12
GR3031473T3 (en) 2000-01-31
AU655436B2 (en) 1994-12-22
RO116621B1 (ro) 2001-04-30
PT99098A (pt) 1992-08-31
SI9210306B (sl) 1998-06-30
SI9210306A (en) 1995-08-31
EP0743302A3 (fr) 1997-03-05
PT99098B (pt) 1999-02-26
JPH04288051A (ja) 1992-10-13
NZ239846A (en) 1994-11-25
ES2100214T3 (es) 1997-06-16
AU8478291A (en) 1992-04-02
FI20011201L (fi) 2001-06-06
FI914534A0 (fi) 1991-09-26
EP0743302B1 (fr) 1999-08-04
GR3023226T3 (en) 1997-07-30
FI108295B (fi) 2001-12-31
US6040317A (en) 2000-03-21
NL990040I2 (nl) 2000-03-01
PL172687B1 (pl) 1997-11-28
US5292756A (en) 1994-03-08
JPH0794425B2 (ja) 1995-10-11
NO913784L (no) 1992-03-30
EP0478363A3 (en) 1992-08-19
IL99540A0 (en) 1992-08-18
NO177702B (no) 1995-07-31
DE69125235T2 (de) 1997-08-07
KR920006313A (ko) 1992-04-27
DE19875054I2 (de) 2007-05-24
RU2116296C1 (ru) 1998-07-27
US5814643A (en) 1998-09-29
BG61810B1 (bg) 1998-06-30
UA44222C2 (uk) 2002-02-15
DE69125235D1 (de) 1997-04-24
HRP930779B1 (en) 2000-08-31
CN1038748C (zh) 1998-06-17
IL99540A (en) 1995-07-31
CA2052073C (fr) 1998-04-14
NO177702C (no) 1995-11-08
NO2000001I2 (no) 2005-09-26
EP0478363A2 (fr) 1992-04-01
FI914534L (fi) 1992-03-28
JPH09132558A (ja) 1997-05-20
IE913383A1 (en) 1992-04-08
CA2052073A1 (fr) 1992-03-28
RU94041739A (ru) 1996-08-10

Similar Documents

Publication Publication Date Title
DE69125235D1 (de) Neue Sulfonamid-Fibrinogen-Rezeptor-Antagonisten
Srinivas et al. Active cell migration drives the unilateral movements of the anterior visceral endoderm
AR011576A1 (es) Compuestos derivados de 1,3,8-triaza-espiro[4,5]decan-4-ona 8-sustituidos; su empleo, un procedimiento para prepararlos y medicamentos que los contienen
ES2063253T3 (es) Fungicidas.
ES2063075T3 (es) Derivados del acido salicilico y sus analogos azufrados.
KR910002863A (ko) Paf 길항작용을 갖는 헤트라제핀, 이의 제조방법 및 의약으로서 이의 용도
Nandan et al. Krüppel-like factor 5 is essential for proliferation and survival of mouse intestinal epithelial stem cells
Weber et al. Migration patterns of avian embryonic bone marrow cells and their differentiation to functional T and B cells
ATE97901T1 (de) Cephalosporinderivate, verfahren zu ihrer herstellung sowie entsprechende pharmazeutische praeparate.
EP0222996A3 (en) 3-amino-dihydro(1)benzopyrane and benzothiopyrane
CO4770959A1 (es) Nuevas sulfonamidas
Graver The polarity of the dental lamina in the regenerating salamander jaw
ES8606258A1 (es) Procedimiento de preparacion de eteres oximas basicos, y de sus sales de adicion acidas farmaceuticamente aceptables
ES2002023A6 (es) Procedimiento para la fabricacion de derivados de 9-(tio-substituido)-4h-pirido(1,2-a)pirimidin-4-ona
DE915231C (de) Elektrisches Gleisbildstellwerk, dessen Gleisbild aus Baukasteneinheiten zusammengesetzt ist
GB1252132A (fr)
ES2059764T3 (es) Derivados de alqueniltetrazol, su preparacion y uso.
EP0372870A3 (fr) Composés pesticides hétérocycliques
Mather Anglican Lutheran relations in Chota Nagpur, 1800-1919, with special reference to 1914-1919: their historical context and theological bearing
Sizer " ECHOES" FROM THE CONSULTATION ROOM.
GB516817A (en) Cabinet for receiving or storing detachable apparatus used in connection with precision grinding machines or lathes
Baker et al. Notes on Air Evacuation
Vaccariello Intraepithelial dynamics in early neoplasia of stratified squamous epithelium
IT1046673B (it) Esteri dell acido triazol tiazoliltion fosforico fosforico procedimento per la loro prefarazione e loro impiego coke insetticiti acaricidi e tioch otoi
DE1662396U (de) Reise-liegestuhl.